Research
Hormonal
GLP-1 receptor agonists and endogenous GLP-1 provide cardiovascular protection by improving endothelial function, reducing blood pressure, and protecting the myocardium.
For individuals with Type 2 Diabetes or high cardiovascular risk, GLP-1 receptor agonists (like liraglutide or semaglutide) are not just glucose-lowering drugs but cardioprotective agents. They improve blood vessel function, lower blood pressure, and reduce the risk of major adverse cardiac events (heart attack, stroke, death).
StrongSupportsVERY_HIGH confidence
GLP-1 or GLP-1 receptor agonists have demonstrated multiple beneficial actions on the heart... long-term treatment with GLP-1 analogs reduces blood pressure... three CV outcome studies showed a significant reduction in a three-point MACE using liraglutide in LEADER, semaglutide in SUSTAIN-6, and recently dulaglutide in REWIND.
Why this rating
Cites large-scale, randomized, double-blind, placebo-controlled outcome trials (LEADER, SUSTAIN-6, REWIND).
Source
Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases
Teresa Salvatore et al. · Nutrients · 2019
narrative_reviewCited 26×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →